Synchron Stock

Synchron, an endovascular brain-computer interface (BCI) firm, has begun patient enrolment for its COMMAND study. The study will assess the safety and efficacy of the Synchron Switch, a BCI device that helps people with limited mobility operate technology using their thoughts. The device is implanted using a minimally-invasive procedure and the study will evaluate its impact on daily tasks such as texting, emailing, and online shopping.

Tom Oxley, a physician and entrepreneur, is developing an implantable brain-computer interface at his company, Synchron. The technology allows a patient's thoughts to be transmitted wirelessly through the skin to control digital devices. Oxley is a neurointerventionist at Mount Sinai Hospital and has performed over 1,600 endovascular neurosurgical procedures.

Paradromics Inc. is developing an electronic brain implant that allows the mind to communicate directly with a computer, aiming to restore the voice of people who have lost the ability to speak or type. The company has attracted investors who believe it can beat Elon Musk's Neuralink to market. Since Musk launched Neuralink in 2017, Paradromics and three other leading companies have raised over $240 million. The technology faces regulatory hurdles and ethical questions, but could potentially offer a cognitive advantage to healthy people who receive an implant.